363 related articles for article (PubMed ID: 16297508)
1. Development of nonhuman adenoviruses as vaccine vectors.
Bangari DS; Mittal SK
Vaccine; 2006 Feb; 24(7):849-62. PubMed ID: 16297508
[TBL] [Abstract][Full Text] [Related]
2. Current strategies and future directions for eluding adenoviral vector immunity.
Bangari DS; Mittal SK
Curr Gene Ther; 2006 Apr; 6(2):215-26. PubMed ID: 16611043
[TBL] [Abstract][Full Text] [Related]
3. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.
Lopez-Gordo E; Podgorski II; Downes N; Alemany R
Hum Gene Ther; 2014 Apr; 25(4):285-300. PubMed ID: 24499174
[TBL] [Abstract][Full Text] [Related]
4. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases.
Alhashimi M; Elkashif A; Sayedahmed EE; Mittal SK
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452358
[TBL] [Abstract][Full Text] [Related]
5. Adenoviruses as vaccine vectors.
Tatsis N; Ertl HC
Mol Ther; 2004 Oct; 10(4):616-29. PubMed ID: 15451446
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral vector immunity: its implications and circumvention strategies.
Ahi YS; Bangari DS; Mittal SK
Curr Gene Ther; 2011 Aug; 11(4):307-20. PubMed ID: 21453277
[TBL] [Abstract][Full Text] [Related]
7. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
Wang WC; Sayedahmed EE; Mittal SK
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730
[TBL] [Abstract][Full Text] [Related]
8. Development of adenoviral vector-based mucosal vaccine against influenza.
Tutykhina IL; Logunov DY; Shcherbinin DN; Shmarov MM; Tukhvatulin AI; Naroditsky BS; Gintsburg AL
J Mol Med (Berl); 2011 Apr; 89(4):331-41. PubMed ID: 21104066
[TBL] [Abstract][Full Text] [Related]
9. Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.
Fougeroux C; Holst PJ
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28420073
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus vectors as recombinant viral vaccines.
Imler JL
Vaccine; 1995 Sep; 13(13):1143-51. PubMed ID: 8578797
[TBL] [Abstract][Full Text] [Related]
11. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
Schagen FH; Ossevoort M; Toes RE; Hoeben RC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
[TBL] [Abstract][Full Text] [Related]
12. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.
Sayedahmed EE; Kumari R; Shukla S; Hassan AO; Mohammed SI; York IA; Gangappa S; Sambhara S; Mittal SK
Vaccine; 2018 Oct; 36(45):6744-6751. PubMed ID: 30266488
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.
Sharma A; Bangari DS; Tandon M; Pandey A; HogenEsch H; Mittal SK
Virology; 2009 Mar; 386(1):44-54. PubMed ID: 19211122
[TBL] [Abstract][Full Text] [Related]
14. Improvements in gene therapy: averting the immune response to adenoviral vectors.
Ritter T; Lehmann M; Volk HD
BioDrugs; 2002; 16(1):3-10. PubMed ID: 11908997
[TBL] [Abstract][Full Text] [Related]
15. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
16. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.
Mandl S; Hix L; Andino R
J Virol; 2001 Jan; 75(2):622-7. PubMed ID: 11134275
[TBL] [Abstract][Full Text] [Related]
17. Adenoviruses as vectors for the transfer of genetic information and for the construction of new type vaccines.
Tikchonenko TI
Adv Exp Med Biol; 1989; 257():193-204. PubMed ID: 2694817
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
Xiang ZQ; Gao GP; Reyes-Sandoval A; Li Y; Wilson JM; Ertl HC
J Virol; 2003 Oct; 77(20):10780-9. PubMed ID: 14512528
[TBL] [Abstract][Full Text] [Related]
19. Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
Abbink P; Kirilova M; Boyd M; Mercado N; Li Z; Nityanandam R; Nanayakkara O; Peterson R; Larocca RA; Aid M; Tartaglia L; Mutetwa T; Blass E; Jetton D; Maxfield LF; Borducchi EN; Badamchi-Zadeh A; Handley S; Zhao G; Virgin HW; Havenga MJ; Barouch DH
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298888
[TBL] [Abstract][Full Text] [Related]
20. Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration.
Fernández E; Toledo JR; Chiong M; Parra F; Rodríguez E; Montero C; Méndez L; Capucci L; Farnós O
Vet Immunol Immunopathol; 2011 Aug; 142(3-4):179-88. PubMed ID: 21621855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
